Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the 12 Best Performing Stocks in the Last 3 Months. On October 16, Oppenheimer raised its price target on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) from $115 to $250 and kept an Outperform rating. This decision came after positive topline results from Praxis Precision Medicines, Inc.’s (NASDAQ:PRAX) 3 Essential3 trial of ulixacaltamide for essential tremor (ET), a nervous system condition that causes involuntary shaking, mostly in the hands and ...

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining more than 100 points on Monday.Shares of Kimberly-Clark Corporation (NYSE:KMB) fell sharply in pre-market trading after the company announced it will acquire Kenvue in a cash and stock transaction with an enterprise value of approximately $48.7 billion.Kimberly-Clark shares dipped 13.6% to $103.50 in pre-market trading.Here are some other stocks moving lower in pre-market trading.uniQure N.V. (NASDAQ:QURE) shares dipped 65.3% to $23 ...

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining more than 100 points on Monday.Shares of Kimberly-Clark Corporation (NYSE:KMB) fell sharply in pre-market trading after the company announced it will acquire Kenvue in a cash and stock transaction with an enterprise value of approximately $48.7 billion.Kimberly-Clark shares dipped 13.6% to $103.50 in pre-market trading.Here are some other stocks moving lower in pre-market trading.uniQure N.V. (NASDAQ:QURE) shares dipped 65.3% to $23 ...

Praxis Precision Medicines, Inc. (PRAX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, ...

Core Insights - Praxis Precision Medicines experienced a significant stock surge of 251% following positive phase 3 trial results for ulixacaltamide, a treatment for essential tremor patients [2][3] - The essential tremor condition affects approximately 10 million Americans, with only one approved treatment currently available, indicating a substantial market opportunity for new therapies [5] - Ulixacaltamide has shown promising results in clinical trials, but the company is still in the pre-commercial stage, which may pose risks for investors [3][15] Company Overview - Praxis Precision Medicines is focused on developing treatments for neurological disorders, with ulixacaltamide targeting essential tremor and vormatrigine aimed at epilepsy [13][14] - The company has a market capitalization of approximately $4 billion, reflecting investor interest in its late-stage drug candidates [12][16] - Praxis recently raised $525 million in a secondary offering, bolstering its cash reserves to support ongoing development efforts [15] Clinical Trial Results - In the first phase 3 study, patients treated with ulixacaltamide showed an average improvement of 4.3 points on a modified Activities of Daily Living test, compared to a 1.7-point improvement in the placebo group [7] - The second study indicated that patients who continued treatment with ulixacaltamide had a significantly higher likelihood of maintaining a response and reported improved disease outcomes [8] - Despite the positive results, a notable discontinuation rate of 35.6% in the first study and 38.1% in the second study raises concerns about treatment tolerability [10][11] Market Potential - The potential annual sales for ulixacaltamide could reach billions, given the large population of underserved essential tremor patients [3] - Up to 77% of essential tremor patients feel inadequately treated, and nearly 50% are not receiving any treatment, highlighting a significant unmet medical need [6] Future Prospects - Praxis is also advancing other drug candidates, including vormatrigine for epilepsy, which has shown promising phase 2 results with a 60% reduction in seizure rates for treated patients [13] - The company is preparing to enter phase 3 trials for vormatrigine, indicating a robust pipeline of potential therapies [14] - Investors with a high-risk tolerance may find Praxis an attractive opportunity due to its focus on underserved populations and multiple late-stage candidates [16]

Core Insights - U.S. stocks experienced a mostly positive session, with the Dow Jones index increasing by over 150 points on Friday [1] Company Highlights - Revolution Medicines Inc (NASDAQ:RVMD) saw a significant share price increase of 11.2%, reaching $55.25, after the FDA granted a non-transferrable voucher for its drug daraxonrasib under the National Priority Voucher pilot program [1] - Disc Medicine Inc (NASDAQ:IRON) shares surged by 25.7% to $93.50 following the receipt of a Commissioner's National Priority Voucher from the FDA for bitopertin [4] - Liberty Energy Inc (NYSE:LBRT) reported a 23.4% increase in share price to $14.73 after announcing third-quarter results [4] - Solana Co (NASDAQ:HSDT) shares rose by 19.5% to $12.08 [4] - Sealsq Corp (NASDAQ:LAES) experienced a 14.4% increase, reaching $7.28 [4] - Rekor Systems Inc (NASDAQ:REKR) shares gained 13.3% to $2.94 [4] - Praxis Precision Medicines Inc (NASDAQ:PRAX) saw a 12.5% increase to $183.00 after announcing a $525 million public offering [4] - Sify Technologies Ltd (NYSE:SIFY) shares rose by 11.8% to $13.15 [4] - Kenvue Inc (NYSE:KVUE) increased by 8.4% to $15.30 [4] - Propetro Holding Corp (NYSE:PUMP) surged by 7.6% to $5.52 [4] - Owens & Minor Inc (NYSE:OMI) shares gained 6.7% to $4.90 [4] - American Express Co (NYSE:AXP) reported a 6% increase in share price to $342.57, surpassing analyst estimates for revenue and adjusted earnings per share [4] - AppFolio Inc (NASDAQ:APPF) shares increased by 4.7% to $233.90, with an upgrade from Keybanc analyst Jason Celino from Sector Weight to Overweight and a new price target of $285 [4]

Core Insights - Praxis Precision Medicines, Inc. (PRAX) shares experienced a significant rally of 183.7%, closing at $162.71, attributed to higher trading volume compared to typical sessions [1] - The stock has gained 30.3% over the past four weeks, indicating strong investor interest [1] Study Results - Positive topline results from two phase III studies of ulixacaltamide for treating essential tremor (ET) were announced, with Study 1 showing a 4.3-point mean improvement in daily functioning at Week 8 compared to placebo, meeting the primary endpoint [2] - Study 2 revealed that 55% of ulixacaltamide-treated patients maintained response compared to 33% on placebo, confirming sustained benefit and meeting the primary endpoint [2] - The drug was well tolerated, with no serious drug-related adverse events reported, positioning ulixacaltamide as a potential first-in-class treatment for ET, which affects around 7 million Americans [2] Regulatory Outlook - Praxis has submitted a pre-NDA meeting request to the FDA, indicating a path toward commercialization, with plans to submit a regulatory application for ulixacaltamide in early 2026 [2] Financial Expectations - The company is expected to report a quarterly loss of $3.45 per share, reflecting a year-over-year change of -25.5%, while revenues are anticipated to be $0.33 million, up 10.7% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, suggesting that stock price movements may not continue without trends in earnings estimate revisions [4] Industry Context - Praxis Precision Medicines is part of the Zacks Medical - Biomedical and Genetics industry, where Royalty Pharma (RPRX) also operates, finishing the last trading session 0.4% higher at $36.34 [4] - Royalty Pharma's consensus EPS estimate for the upcoming report has changed by +0.8% over the past month to $1.11, representing a year-over-year change of +6.7% [5]

Core Viewpoint - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues, particularly when ad-blockers are enabled [1] Group 1 - The article suggests that users may face restrictions if they have ad-blockers enabled, indicating a need for adjustments in browser settings [1]

Core Viewpoint - Praxis Precision Medicines, Inc. has announced a public offering of 3,025,480 shares of common stock priced at $157.00 per share, along with pre-funded warrants for an additional 318,470 shares, aiming to raise approximately $525 million in gross proceeds before expenses [1] Group 1: Offering Details - The offering includes 3,025,480 shares of common stock priced at $157.00 each and pre-funded warrants to purchase up to 318,470 shares at a price of $156.9999 per warrant [1] - The gross proceeds from the offering are expected to be around $525 million, excluding underwriting discounts and commissions [1] - Praxis has granted underwriters a 30-day option to purchase up to 501,592 additional shares at the public offering price [1] Group 2: Underwriters - TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering [2] - Oppenheimer & Co. and H.C. Wainwright & Co. are serving as lead managers for the offering [2] Group 3: Regulatory Information - The offering is made under a shelf registration statement on Form S-3ASR, which became effective upon filing with the SEC on December 23, 2024 [3] - A preliminary prospectus supplement was filed with the SEC on October 16, 2025, with the final prospectus supplement to be filed subsequently [3]

Group 1 - The conference call is focused on the Essential3 Topline Results from Praxis Precision Medicines [1][2] - The call is being webcast live and can be accessed on the Investors section of Praxis' website [2] - Forward-looking statements may be included, reflecting the company's future expectations and plans [3] Group 2 - The company emphasizes that forward-looking statements should not be relied upon as future representations [3] - Praxis may update its forward-looking statements in the future but is not obligated to do so [3] - Recent filings with the Securities and Exchange Commission provide details on risks and uncertainties associated with the company's business [3]